NicOx pushes new naproxen version for arthritis pain
The Wall Street Journal reports on the progress that NicOx is making advancing a new version of naproxen for relieving arthritis pain. The French biotech is looking for a marketing partner for the drug, which adds nitric oxide to naproxen, relaxing blood vessel walls in a way that will allow patients to take the drug without the risk of higher blood pressure.
"We'll be the only one that will be able to show we're like placebo on blood pressure in long-term trials," said Michele Garufi, CEO of NicOxthe. NicOx may file for approval in early 2009.
- read the report from the Wall Street Journal's blog
Related Articles:
NicOx osteoarthritis drug fails comparison study. Report
NicOx escapes a requirement for major trial. Report
NicOx stock soars on $385M development pact. Report
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends